A new modification of histone H3 affects gene expression in breast cancer.
Official title: A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer
Funded at Ut Southwestern Medical Center · NIH-10978212 · Data updated 2026-11-12
This study is looking at a new change in a protein that might affect how genes work in breast cancer cells, and by understanding this better, we hope to find new ways to treat the disease that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | December 8, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $427,721 |
| NIH project number | 5R01CA274924-03 |
| Project ID | NIH-10978212 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with breast cancer who may benefit from novel therapeutic approaches targeting epigenetic regulation.
✕Less likely to help
Patients with non-breast cancer types or those not diagnosed with cancer may not receive any benefit from this research.
What this research studies
This research investigates how a newly identified modification of histone H3, specifically hydroxylation on proline 16, influences gene expression and epigenetic programming in breast cancer. The study aims to understand the role of this modification in recruiting specific proteins that regulate gene expression, which may lead to changes in cancer cell behavior. By examining breast cancer cells, the researchers will explore the molecular mechanisms involved and how this modification interacts with key signaling pathways. Patients may benefit from insights gained into the underlying biology of breast cancer, potentially leading to new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that target the epigenetic mechanisms involved in breast cancer.
How similar studies have gone: While the specific modification being studied is novel, previous research has shown that targeting epigenetic modifications can be effective in cancer treatment.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Zhang, Qing — Ut Southwestern Medical Center
- Study coordinator: Zhang, Qing
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.